Guggenheim Maintains Buy on AbbVie, Raises Price Target to $288

Benzinga · 08/04 11:48
Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $261 to $288.